

Resource Summary Report

Generated by [RRID](#) on Aug 4, 2026

TIMER

RRID:SCR_018737

Type: Tool

Proper Citation

TIMER (RRID:SCR_018737)

Resource Information

URL: <https://cistrome.shinyapps.io/timer/>

Proper Citation: TIMER (RRID:SCR_018737)

Description: Web server for comprehensive analysis of tumor infiltrating immune cells. Web tool for systematical analysis of immune infiltrates across diverse cancer types. Allows users to input function specific parameters, with resulting figures dynamically displayed to access tumor immunological, clinical, and genomic features.

Abbreviations: TIMER

Synonyms: Tumor IMmune Estimation Resource

Resource Type: production service resource, web service, analysis service resource, data access protocol, service resource, software resource

Defining Citation: [PMID:29092952](#)

Keywords: Tumor, tumor infiltrating immune cell, immune cell, cell, analysis, cancer cell, cancer type, tumor immunological feature, tumor genomic feature, display

Funding: National Natural Science Foundation of China ;
NCI CA180980;
Dana-Farber Cancer Institute

Availability: Free, Freely available

Resource Name: TIMER

Resource ID: SCR_018737

Record Creation Time: 20220129T080341+0000

Record Last Update: 20260804T043705+0000

Ratings and Alerts

No rating or validation information has been found for TIMER.

No alerts have been found for TIMER.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 2042 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Al-Mathkour MM, et al. (2026) The YAP1 and EPHA3 receptor tyrosine kinase axis regulates cellular plasticity and treatment response. Cellular signalling, 141, 112368.

Hu YM, et al. (2026) Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types. Cancer research communications, 6(1), 17.

Luo M, et al. (2025) Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations. Cancer discovery, 15(3), 511.

Xu Z, et al. (2025) A Prognostic Risk Signature Based on Myeloid-Derived Suppressor Cells and Regulatory T Cells in Clear Cell Renal Cell Carcinoma. Technology in cancer research & treatment, 24, 15330338251382839.

Withers HG, et al. (2025) Intratumoral B cell and interferon signatures in newly diagnosed glioblastoma are associated with longer survival in patients treated with SurVaxM. Cancer immunology, immunotherapy : CII, 74(11), 332.

Mehta V, et al. (2025) Database analysis reveals endophilin A expression as a marker of metastasis and prognosis in breast cancer. Discover oncology, 16(1), 1832.

Luo B, et al. (2025) Resveratrol amplifies the anti-tumor effect of ?-PD-1 by altering the intestinal microbiome and PGD2 content. Gut microbes, 17(1), 2447821.

Bergsma P, et al. (2025) Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion-Defined Rhabdomyosarcoma. Molecular cancer therapeutics, 24(12), 1989.

Egea-Rodriguez S, et al. (2025) RECQL4 affects MHC class II-mediated signalling and favours an immune-evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma. Clinical and translational medicine, 15(1), e70094.

Kang N, et al. (2025) Exploring B7-H4's Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities. *Molecular cancer research : MCR*, 23(4), 327.

Zhang C, et al. (2025) Bioinformatics insights into ACSL1 and ACSL5: prognostic and immune roles in low-grade glioma. *BMC cancer*, 25(1), 226.

Wu Z, et al. (2025) The efficacy of Sijunzi on immune function in patients with gastrointestinal cancers after surgery: Integrating systematic review and network pharmacology. *Medicine*, 104(6), e41419.

Wang C, et al. (2025) Prognostic value of IFI27 in HNSCC and functional analysis under ALKBH5 regulation. *Scientific reports*, 15(1), 6606.

Yu R, et al. (2025) ATRX mutation modifies the DNA damage response in glioblastoma multiforme tumor cells and enhances patient prognosis. *Medicine*, 104(2), e41180.

Peng L, et al. (2025) Establishment and verification of a prognostic signature associated with fatty acid metabolism in endometrial cancer. *Molecular medicine reports*, 31(3).

Li J, et al. (2025) Integrated multiomics analysis highlights the immunosuppressive role of granulysin precursor positive macrophages in hepatocellular carcinoma. *PeerJ*, 13, e18879.

Zhang X, et al. (2025) LPIN3 promotes colorectal cancer growth by dampening intratumoral CD8⁺ T cell effector function. *Cancer immunology, immunotherapy : CII*, 74(4), 135.

Nagase Y, et al. (2025) CXCL9 and CXCL13 shape endometrial cancer immune-activated microenvironment via tertiary lymphoid structure formation. *Cancer science*, 116(5), 1193.

Zhang L, et al. (2025) Transcriptional Regulation of NUPR1 by MYH11 Activates PI3K/AKT and Promotes Bladder Cancer Progression Through Ferroptosis and M2 Polarization of Macrophages. *Technology in cancer research & treatment*, 24, 15330338241305434.

Ding YF, et al. (2025) Cyclic increase in the histamine receptor H1-ADAM9-Snail/Slug axis as a potential therapeutic target for EMT-mediated progression of oral squamous cell carcinoma. *Cell death & disease*, 16(1), 191.